Business
RepliCel CEO Provides 2019 Shareholder Update
RepliCel CEO Provides 2019 Shareholder Update.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel CEO Provides 2019 Shareholder Update\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel CEO Provides 2019 Shareholder Update\nPR Newswire\nVANCOUVER, March 5, 2019\n\n\n\nWith a new strategic plan, RepliCel prioritizes focus on commercial revenue\n VANCOUVER, March 5, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (\"RepliCel\" or the \"Company\"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler.\n\n\nDear Shareholders,\nI am pleased to be providing this much-anticipated 2019 update. \nFirst, a quick recap of our Annual General Meeting held December 14, 2018 at which the shareholders elected a new slate of directors to RepliCel's Board - some re-elected, some new. The Board now has higher shareholder representation as well as a duly-elected nominee of our new investor/partner in Greater China. \nStrategic Planning\nManagement and the Board have spent the past 60 days conducting an end-to-end analysis of the Company and its programs followed by comprehensive strategic planning to establish the Company's direction and priorities for the next 24-36 months. \nA recent Board meeting solidified the analysis and strategic plan. We have emerged from this process with clarity around our strategy that we are eager to communicate with shareholders and the broader marketplace. \nOur core message is this: RepliCel's strategy drives the Company toward revenue and the Board's objective of minimizing the need for capital and dilution until the Company is revenue generating. \nTransition to Commercial Revenue\nRepliCel's focus on its transition to commercial revenue leads the Company to prioritize commercialization of the Company's dermal injector (and consumables) as well as clinical development of the tendon and skin programs in Japan where the pathway to commercial launch is the shortest due to its unique regulatory framework for cell therapies. \nRepl...